Effects of metformin in obese patients with impaired glucose tolerance (Q40927906)

24 September 2017

1 reference

title

Effects of metformin in obese patients with impaired glucose tolerance (English)

1 reference

24 September 2017

0 references

1 reference

Scheen AJ

1

1 reference

24 September 2017

Letiexhe MR

series ordinal

2

1 reference

24 September 2017

Lefèbvre PJ

series ordinal

3

1 reference

24 September 2017

language of work or name

1 reference

1 September 1995

1 reference

Diabetes/metabolism reviews

24 September 2017

1 reference

24 September 2017

11 Suppl 1

1 reference

24 September 2017

S69-80

1 reference

Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM?

24 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Pathogenesis of NIDDM. A balanced overview

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

https://api.crossref.org/works/10.1002%2FDMR.5610110511

1 reference

7 January 2021

Management of non-insulin-dependent diabetes mellitus in Europe: a concensus view

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Management of Non-Insulin-Dependent Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Animal models of obesity--theories of aetiology

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Quantitative study of insulin secretion and clearance in normal and obese subjects

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

How to measure insulin clearance

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Assessment of Insulin Resistance in vivo: Application to the Study of Type 2 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin sensitivity in anorexia nervosa: a mirror image of obesity?

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Impact of obesity on insulin action in NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Metabolic origin of insulin resistance in obesity with and without type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

How to measure insulin secretion

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

How to measure insulin action in vivo

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Relationship of insulin clearance and secretion to insulin sensitivity in non-diabetic Mexican Americans

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin resistance in obesity is associated with elevated basal lactate levels and diminished lactate appearance following intravenous glucose and insulin

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy?

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Natural history of beta-cell dysfunction in NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Banting lecture 1990. Beta-cells in type II diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Loss of the first phase insulin response to intravenous glucose in subjects with persistent impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin sensitivity, insulin secretion, and glucose effectiveness in subjects with impaired glucose tolerance: a minimal model analysis.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance. Insulin Resistance Atherosclerosis Study

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Glucose effectiveness in two subtypes within impaired glucose tolerance. A minimal model analysis.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin-sensitive and insulin-resistant variants in NIDDM.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Cellular mechanism of action of metformin

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Correlation of in vivo and in vitro actions of insulin in obesity and noninsulin-dependent diabetes mellitus: role of the glucose transport system

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Glucose transport and NIDDM

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Treating insulin resistance in hypertension with metformin reduces both blood pressure and metabolic risk factors

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

1 reference

https://api.crossref.org/works/10.1002%2FDMR.5610110511

7 January 2021

Identifiers

DOI

10.1002/DMR.5610110511

1 reference

24 September 2017

1 reference